CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...
There is no shortage of ASX healthcare companies with upcoming catalysts – a focal point for investors. ... Read More The ...
The EC made its decision following the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use, ...
Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...
Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical ...
Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...
MIPLYFFA was further granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. MIPLYFFA is indicated for use in combination with miglustat for the ...
submission to the European Medicines Agency (EMA) in 2026, assuming positive study results. Additionally, Quince was granted Fast Track designation by the FDA for the company's EryDex System for the ...
DARMSTADT, Germany I 12, 2024 I Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an ...
Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a GMP ...